These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 12533677

  • 1. Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells.
    Deeb D, Xu YX, Jiang H, Gao X, Janakiraman N, Chapman RA, Gautam SC.
    Mol Cancer Ther; 2003 Jan; 2(1):95-103. PubMed ID: 12533677
    [Abstract] [Full Text] [Related]

  • 2. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria.
    Gao X, Deeb D, Jiang H, Liu YB, Dulchavsky SA, Gautam SC.
    J Exp Ther Oncol; 2005 Jan; 5(1):39-48. PubMed ID: 16416600
    [Abstract] [Full Text] [Related]

  • 3. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis.
    Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA, Gautam SC.
    J Exp Ther Oncol; 2005 Jan; 5(2):81-91. PubMed ID: 16471035
    [Abstract] [Full Text] [Related]

  • 4. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation.
    Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky SA, Gautam SC.
    Mol Cancer Ther; 2004 Jul; 3(7):803-12. PubMed ID: 15252141
    [Abstract] [Full Text] [Related]

  • 5. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 6. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
    Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB.
    Prostate; 2002 Jun 01; 52(1):1-11. PubMed ID: 11992615
    [Abstract] [Full Text] [Related]

  • 7. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C, King DL, Norris JS.
    Cancer Gene Ther; 2002 Feb 01; 9(2):164-72. PubMed ID: 11857034
    [Abstract] [Full Text] [Related]

  • 8. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S, Almasan A.
    Cancer Res; 2003 Aug 01; 63(15):4713-23. PubMed ID: 12907654
    [Abstract] [Full Text] [Related]

  • 9. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Munshi A, McDonnell TJ, Meyn RE.
    Cancer Chemother Pharmacol; 2002 Jul 01; 50(1):46-52. PubMed ID: 12111111
    [Abstract] [Full Text] [Related]

  • 10. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT.
    Cancer Res; 2001 Feb 15; 61(4):1645-51. PubMed ID: 11245478
    [Abstract] [Full Text] [Related]

  • 11. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
    Eid MA, Lewis RW, Kumar MV.
    Mol Cancer Ther; 2002 Aug 15; 1(10):831-40. PubMed ID: 12492116
    [Abstract] [Full Text] [Related]

  • 12. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
    Ng CP, Bonavida B.
    Mol Cancer Ther; 2002 Oct 15; 1(12):1051-8. PubMed ID: 12481428
    [Abstract] [Full Text] [Related]

  • 13. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5).
    Jung EM, Lim JH, Lee TJ, Park JW, Choi KS, Kwon TK.
    Carcinogenesis; 2005 Nov 15; 26(11):1905-13. PubMed ID: 15987718
    [Abstract] [Full Text] [Related]

  • 14. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
    Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.
    Oncogene; 2001 Sep 20; 20(42):6073-83. PubMed ID: 11593415
    [Abstract] [Full Text] [Related]

  • 15. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells.
    Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E, Dimanche-Boitrel MT.
    Oncogene; 2003 Mar 27; 22(12):1807-16. PubMed ID: 12660816
    [Abstract] [Full Text] [Related]

  • 16. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H.
    Cell Death Differ; 2004 Jul 27; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway.
    Hu H, Jiang C, Schuster T, Li GX, Daniel PT, Lü J.
    Mol Cancer Ther; 2006 Jul 27; 5(7):1873-82. PubMed ID: 16891474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.